GLP-1 receptor agonist effects on lipid and liver profiles in patients with nonalcoholic fatty liver disease: systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Abstract
Aims. This meta‐analysis of randomized placebo‐controlled clinical trials assessed the effect of glucose‐like peptide‐1‐receptor agonists (GLP‐1RA) on the lipid profile and liver enzymes in patients with nonalcoholic fatty liver disease (NAFLD). Materials and Methods. Randomized placebo‐controlled trials investigating GLP‐1RA on the lipid profile and liver enzymes in patients with NAFLD were searched in PubMed‐Medline, Scopus, Web of Science, and Google Scholar databases (from inception to January 2020). A random‐effects model and a generic inverse variance method were used for quantitative data synthesis. Sensitivity analysis was conducted. Weighted random‐effects meta‐regression was performed on potential confounders on lipid profile and liver enzyme concentrations. Results. 12 studies were identified (12 GLP‐1RA arms; 677 subjects) that showed treatment with GLP‐1RA reduced alanine transaminase (ALT) concentrations (WMD = −10.14, 95%CI = [−15.84, −0.44], P < 0.001), gamma‐glutamyl transferase (GGT) (WMD = −11.53, 95%CI = [−15.21,−7.85], P < 0.001), and alaline phosphatase (ALP) (WMD = −8.29, 95%CI = [−11.34, −5.24], P < 0.001). Aspartate aminotransferase (AST) (WMD = −2.95, 95% CI = [−7.26, 1.37], P = 0.18) was unchanged. GLP‐1 therapy did not alter triglycerides (TC) (WMD = −7.07, 95%CI = [−17.51, 3.37], P = 0.18), total cholesterol (TC) (WMD = −1.17 (−5.25, 2.91), P = 0.57), high‐density lipoprotein (HDL‐C) (WMD = 0.97, 95%CI = [−1.63, 3.58], P = 0.46), or low‐density lipoprotein (LDL‐C) (WMD = −1.67, 95%CI = [−10.08, 6.74], P = 0.69) in comparison with controls. Conclusion. The results of this meta‐analysis suggest that GLP‐1RA treatment significantly reduces liver enzymes in patients with NAFLD, but the lipid profile is unaffected.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The effect of semaglutide and other single GLP-1RAs on triglycerides and HDL is generally modest,126 despite the significant weight loss, while it is better with tirzepatide.127”
From Lipid metabolism in MASLD and MASH: From mechanism to the clinic (2024) · cites this paper as [126]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305 · cited 1×
“*e overall evaluation of the evidence relating to the outcomes was conducted by the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach (Table 2) [25].”
Cochrane Handbook for Systematic Reviews of Interventions
(2019) · doi:10.1002/9781119536604 · Cited by 14,828
Borenstein, M., Hedges, L. V., Higgins, J. P. T., & Rothstein, H. R. (2009) · doi:10.1002/9780470743386 · Cited by 14,225
Cumpston, M., Li, T., Page, M. J., Chandler, J., Welch, V. A., Higgins, J. P., & Thomas, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.ed000142 · Cited by 7,218
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
Vrabel, M. (2015) · Oncology Nursing Forum · doi:10.1188/15.onf.552-554 · Cited by 669
Research works printed but not linked: 2
- WangD. J. J. M. U. Effect of exenatide combined with metformin therapy on insulin resistance liver function and inflammatory response in patients with type 2 diabetes mellitus combined with NAFLD Journal of Hainan Medical University 2017 23 no. 18 44–47.
- Khoo J., 2019, Comparing effects of liraglutide-induced weight loss versus lifestyle modification on liver fat content and plasma acylcarnitine levels in obese adults with nonalcoholic fatty liver disease, Obesity Facts, 12
Cited by
Pouwels, S., Sakran, N., Graham, Y., Leal, A., Pintar, T., Yang, W., Kassir, R., Singhal, R., Mahawar, K., & Ramnarain, D. (2022) · BMC Endocrine Disorders · doi:10.1186/s12902-022-00980-1 · Cited by 897
Lipid metabolism in MASLD and MASH: From mechanism to the clinic
Carli, F., Della Pepa, G., Sabatini, S., Vidal Puig, A., & Gastaldelli, A. (2024) · JHEP Reports · doi:10.1016/j.jhepr.2024.101185 · Cited by 147
Noninvasive serum biomarkers for liver fibrosis in NAFLD: current and future
Reinson, T., Buchanan, R. M., & Byrne, C. D. (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0348 · Cited by 75
Anti-inflammatory benefits of semaglutide: State of the art
Yaribeygi, H., Maleki, M., Jamialahmadi, T., & Sahebkar, A. (2024) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2024.100340 · Cited by 72
Self-citationArvanitakis, K., Koufakis, T., Kotsa, K., & Germanidis, G. S. (2022) · Cancers · doi:10.3390/cancers14194651 · Cited by 63
Yang, C., Yao, W., Yang, C., Peng, Z., Ou, H., & Kuo, S. (2024) · Journal of Internal Medicine · doi:10.1111/joim.13751 · Cited by 42
Gu, Y., Sun, L., Zhang, W., Kong, T., Zhou, R., He, Y., Deng, C., Yang, L., Kong, J., Chen, Y., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1102792 · Cited by 50
Najafi, S., Bahrami, M., Butler, A. E., & Sahebkar, A. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15344 · Cited by 39
Self-citationLiver Protective Effect of Fenofibrate in NASH/NAFLD Animal Models
Mahmoudi, A. A., Moallem, S. A., Johnston, T. P., & Sahebkar, A. (2022) · PPAR Research · doi:10.1155/2022/5805398 · Cited by 40
Self-citationThe immune response as a therapeutic target in non-alcoholic fatty liver disease
Ortiz‐López, N., Fuenzalida, C., Dufeu, M. S., Pinto-León, A., Escobar, A. F., Poníachik, J., Roblero, J. P., Valenzuela-Pérez, L., & Beltrán, C. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.954869 · Cited by 40
HDL abnormalities in type 2 diabetes: Clinical implications
Martagón, A. J., Zubirán, R., González-Arellanes, R., Praget-Bracamontes, S., Rivera-Alcántara, J. A., & Aguilar-Salinas, C. A. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117213 · Cited by 34
Luo, Q., Wei, R., Cai, Y., Zhao, Q., Liu, Y., & Liu, W. J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.793203 · Cited by 28
The role of PCSK9 in NAFLD/NASH and therapeutic implications of PCSK9 inhibition
Momtazi‐Borojeni, A. A., Banach, M., Ruscica, M., & Sahebkar, A. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2132229 · Cited by 28
Self-citationPatoulias, D., Michailidis, T., Dimosiari, A., Fragakis, N., Tse, G., & Rizzo, M. (2023) · Biomedicines · doi:10.3390/biomedicines11030669 · Cited by 31
Mao, X., Zhang, X., Lai, R., Cheung, K. S., Yuen, M., Cheung, R. C., Seto, W., & Nguyen, M. H. (2025) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2024.1096 · Cited by 36
Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes
Ma, Z., Jin, K., Yue, M., Chen, X., & Chen, J. (2023) · Journal of Diabetes Research · doi:10.1155/2023/5891532 · Cited by 29
Rivera, F. B., Chin, M. N. C., Pine, P. L. S., Ruyeras, M. M. J., Galang, D. J. C., Gandionco, K. M., Morales, B. L. F. D., Climaco, Z. M. V., Bantayan, N. R. B., Magalong, J. V., et al. (2024) · Current Medical Research and Opinion · doi:10.1080/03007995.2024.2442027 · Cited by 19
Byrne, C. D. (2022) · Diabetic Medicine · doi:10.1111/dme.14912 · Cited by 18
Tamilwanan, S., Aziz, Z., Rong, L. Y., Bitar, A. N., Zarzour, R. A., & Alshehade, S. A. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04358-0 · Cited by 26
Ajabnoor, G., Hashim, K. T., Alzahrani, M. M., Alsuheili, A. Z., Alharbi, A. F., Alhozali, A. M., Enani, S. M., Eldakhakhny, B. M., & Elsamanoudy, A. Z. (2023) · Diseases · doi:10.3390/diseases11010050 · Cited by 20
Exploring the antioxidant properties of semaglutide: A comprehensive review
Yaribeygi, H., Maleki, M., Forouzanmehr, B., Kesharwani, P., Jamialahmadi, T., Karav, S., & Sahebkar, A. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108906 · Cited by 14
Self-citationGameil, M. A., Yousef, E. A. A. M., Marzouk, R. E., Emara, M., Abdelkader, A. H., & Salama, R. I. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01526-2 · Cited by 16
Ahmed, M., & Ahmed, M. H. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13133893 · Cited by 13
Potter, K. J., Phinney, J., Kulai, T. B., & Munro, V. (2025) · Journal of the Canadian Association of Gastroenterology · doi:10.1093/jcag/gwae057 · Cited by 18
Pantanetti, P., Ronconi, V., Sguanci, M. E., Palomares, S. M., Mancin, S., Tartaglia, F. C., Cangelosi, G., & Petrelli, F. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164752 · Cited by 12
NLRP3 inflammasomes pathway: a key target for Metformin
Hosseini, Y., Niknejad, A., Kashani, A. S., Gholami, M., Roustaei, M., Mohammadi, M. K., Momtaz, S., Atkin, S. L., Jamialahmadi, T., Abdolghaffari, A. H., et al. (2025) · Inflammopharmacology · doi:10.1007/s10787-025-01702-4 · Cited by 13
Self-citationMyeloid cell path to malignancy: insights into liver cancer
Ramirez, C. F. A., & Akkari, L. (2025) · Trends in cancer · doi:10.1016/j.trecan.2025.02.006 · Cited by 11
Impact of Semaglutide Administration on Weight Loss After Bariatric Surgery: A Meta-Analysis
Jamialahamdi, T., Mirhadi, E., Almahmeed, W. A., Virani, S. S., Eid, A. H., Al‐Rasadi, K., Salehabadi, S., & Sahebkar, A. (2025) · Obesity Surgery · doi:10.1007/s11695-025-07848-y · Cited by 10
Self-citationCao, Y., Cao, S., Zhao, J., Zhao, J., Zhao, Y., & Liu, Y. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1387993 · Cited by 7
Borges, R. D. S., de Abreu, E. S., Berton, G. G., de Paula, L. H., Conegundes, A. F., Martins, J. M. B., Martins, M. A. B., Dahbour, A., Fernandes, M. V., & Abdelmalek, M. F. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101708 · Cited by 14
Is Tirzepatide the New Game Changer in Type 2 Diabetes?
Lisco, G., Disoteo, O., Geronimo, V. D., Tullio, A. D., Giagulli, V. A., Guastamacchia, E., Pergola, G. D., Jirillo, E., & Triggiani, V. (2024) · Endocrines · doi:10.3390/endocrines5010005 · Cited by 8
Glp-1 Mimetics and Autophagy in Diabetic Milieu: State-of-the-Art
Yaribeygi, H., Maleki, M., Santos, R. D., Jamialahmadi, T., & Sahebkar, A. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998276570231222105959 · Cited by 8
Self-citationParkinson’s disease and brain insulin signaling: Mechanisms and potential role of GLP-1 mimetics
Foroozanmehr, B., Hemmati, M. A., Yaribeygi, H., Karav, S., Jamialahmadi, T., & Sahebkar, A. (2025) · Brain Research · doi:10.1016/j.brainres.2025.149738 · Cited by 6
Self-citationYao, Y., Liu, N., Chen, S., Sun, M., & Guo, Y. (2025) · European journal of medical research · doi:10.1186/s40001-025-03241-8 · Cited by 7
Pal, B., & Chattopadhyay, M. (2024) · Journal of Diabetology · doi:10.4103/jod.jod_117_23 · Cited by 8
NLRP3 inflammasome as a central target for the pleiotropic effects of GLP-1 receptor agonists
Mahmoudi, A. A., Saeedi‐Boroujeni, A., Vadizadeh, A., Kesharwani, P., & Sahebkar, A. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117063 · Cited by 4
Self-citationMahmoudi, A. A., Butler, A. E., Orekhov, A. N., Jamialahmadi, T., & Sahebkar, A. (2023) · Current Medicinal Chemistry · doi:10.2174/0929867331666230829164832 · Cited by 6
Self-citationHepatic effects of GLP-1 mimetics in diabetic milieu: A mechanistic review of involved pathways
Yaribeygi, H., Kashian, K., Moghaddam, K. I., Karim, S. R., Bagheri, N., Karav, S., Jamialahmadi, T., Rizzo, M., & Sahebkar, A. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108928 · Cited by 4
Self-citationReinson, T., Patel, J., Mathews, M., Fountain, D., Buchanan, R. M., & Byrne, C. D. (2023) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00335 · Cited by 7
GLP-1 mimetics and diabetic ketoacidosis: possible interactions and clinical consequences
Forouzanmehr, B., Hemmati, M. A., Atkin, S. L., Jamialahmadi, T., Yaribeygi, H., & Sahebkar, A. (2025) · Naunyn-Schmiedeberg's Archives of Pharmacology · doi:10.1007/s00210-024-03384-1 · Cited by 3
“Besides, these drugs have been reported to exert diverse pharmacological effects that may extend beyond T2DM management (Yaribeygi et al. 2021, 2020, 2019b, 2020b; Rezaei et al. 2021; Ashrafizadeh et al. 2019; Ran-jbar et al. 2019).”
Self-citationAlbargawi, M. S., Alharbi, R. N., Alajlani, M. A., Abdulaal, I., & Aldakhil, L. O. (2024) · Journal of Epidemiology and Global Health · doi:10.1007/s44197-024-00207-7 · Cited by 4
Cell and gene therapeutic approaches in non-alcoholic fatty liver disease
Poudineh, M., Mohammadyari, F., Parsamanesh, N., Jamialahmadi, T., Kesharwani, P., & Sahebkar, A. (2025) · Gene · doi:10.1016/j.gene.2025.149466 · Cited by 3
Self-citationAn update on the therapeutic role of RNAi in NAFLD/NASH
Dehghan, H., Ghasempour, A., Akbar-Abad, M. S., Khademi, Z., Sedighi, M., Jamialahmadi, T., & Sahebkar, A. (2023) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.12.005 · Cited by 3
Self-citationGLP-1 and GIP in Type 1 Diabetes Therapy: A Time for Reappraisal?
Piras, G., Brasili, S., Demontis, D., Sala, L. D., Cocchiara, F., Maggi, D. C., & Arecco, A. (2026) · Diabetology · doi:10.3390/diabetology7030050 · Cited by 2
Kotb, W. M. E., Hanafy, N. F., Waan, W. E., & Shokr, E. A. (2022) · Egyptian Journal of Health Care · doi:10.21608/ejhc.2022.342070 · Cited by 3
Cao, W., Jiang, T., Deng, W., Wang, S., Li, X., Zhang, Z., Zhang, L., Yao, L., Chang, M., Liu, R., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1384927 · Cited by 3
Yaghmayee, S., Moazzeni, A. S., Jamialahmadi, T., Karav, S., Yaribeygi, H., Kesharwani, P., & Sahebkar, A. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.06.009 · Cited by 2
Self-citationPantanetti, P., Ronconi, V., Mancin, S., Carolis, C. D., Alberti, S., Pazzi, O., Marco, S. D., Michetti, G., Coacci, S., Mignini, V. E., et al. (2025) · Diabetology · doi:10.3390/diabetology6080080 · Cited by 3
Incretins and the metabolic syndrome
Karásek, D. (2024) · Vnitřní lékařství · doi:10.36290/vnl.2024.020 · Cited by 1
Armes, S., Tibaes, J., Rajaram, R., Ruddock, M. W., Kurth, M. J., FitzGerald, P. S., Golubić, R., & Ray, S. (2025) · BMJ Nutrition Prevention & Health · doi:10.1136/bmjnph-2025-001236 · Cited by 4
Chernyavskyi, V. V., Akimov, A., Tishchenko, V. V., & Parunian, L. M. (2025) · GASTROENTEROLOGY · doi:10.22141/2308-2097.59.4.2025.705 · Cited by 1
Hertzer, L., Siegel, R., Kharofa, R. Y., Stackpole, K., & Mahabee‐Gittens, E. M. (2026) · Childhood Obesity · doi:10.1177/21532176251413898 · Cited by 3
Elnaggar, M. N., Abbas, O. F., Almarfadi, A., Refaei, A., Eltaly, H., & Aziz, M. A. E. (2026) · Current Hepatology Reports · doi:10.1007/s11901-025-00718-2 · Cited by 1
Yaribeygi, H., Maleki, M., Kesharwani, P., Jamialahmadi, T., & Sahebkar, A. (2026) · International Journal of Clinical Practice · doi:10.1155/ijcp/2770814 · Cited by 1
Self-citationZou, M., & Liu, C. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02179-z · Cited by 1
Mechanisms of GLP‒1 Receptor Agonists on the Cardio-Renal Protective Effects
Kuriyama, S., & Matsumoto, K. (2022) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.53.6_249
Dual GIP and GLP-1 agonists and changes in the lipid spectrum
Karásek, D. (2024) · Vnitřní lékařství · doi:10.36290/vnl.2024.006
Basil, B., Mohammed, J. A., Mba, I. N., Okoro, N. I., Myke-Mbata, B. K., & Akujieze, C. J. (2025) · Research Square · doi:10.21203/rs.3.rs-7806539/v1
Gül, A., Özkan, H., Güvenç, M., & Çalışır, T. (2025) · Interdisciplinary Medical Journal · doi:10.17944/interdiscip.1782720
Chondroprotective Effect of Semaglutide in Osteoarthritis: Association with Macrophage Polarization
Lei, D., Pang, C., Huang, H., He, Z., & Lu, L. (2026) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2026.145015
Wu, H., Zhang, Z., Ye, T., Chen, J.-N., Tung, T., & Zhu, J. F. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1783429
THE DARK SIDE OF GLP-1 ANALOGS: ADVERSE EFFECTS, LIMITATIONS, AND SAFETY CONCERNS
Dudzińska, K., Kaftan, A., Plenikowski, J., Kahsin, A., Kacprzak, S., Greluk, A., Żuk, J., Ciszewski, W., Jurewicz, A., & Plenikowska, Z. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5655
Jo, D., Song, D. J., Jeong, S. W., & Song, J. (2026) · Current Molecular Pharmacology · doi:10.1016/j.cmp.2026.09.011
GLP-1 as a Regulator of Oxidative Signalling in Metabolic Health and Disease
Kurhaluk, N., Kołodziejska, R., & Ткаченко, Г. М. (2026) · Antioxidants · doi:10.3390/antiox15101283 · Cited by 1
Mikhael, F. G., Ayoub, C., Teperikidis, E., Biondi-Zoccai, G., Booz, G. W., Zouein, F. A., & Makarem, N. N. (2026) · Current Atherosclerosis Reports · doi:10.1007/s11883-026-01471-7
Metadata
- Authors
- Rezaei, S., Tabrizi, R., Nowrouzi-Sohrabi, P., Jalali, M., Atkin, S. L., Al-Rasadi, K., Jamialahmadi, T., & Sahebkar, A.
- Affiliations
- Shiraz University (IR)
- Fasa University of Medical Sciences (IR)
- Shiraz University of Medical Sciences (IR)
- Weill Cornell Medical College in Qatar (QA)
- Mashhad University of Medical Sciences (IR)
- Corresponding author
- Sahebkar, Amirhossein
- ORCID
- Venue
- Canadian Journal of Gastroenterology and Hepatology
- Publisher
- Wiley
- Published
- 2021-01
- Volume
- 2021
- Issue
- 1
- Pages
- 8936865-8936865
- ISSN
- 2291-2789 (ISSN-L)
- 2291-2797
- PMC
- PMC8604595
- OpenAlex
- W3211702740
- Cited by
- 65
- References
- 43
- Citations by year
- 2026: 12 · 2025: 16 · 2024: 17 · 2023: 9 · 2022: 11
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Canadian Journal of Gastroenterology and Hepatology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- GLP-1 receptor agonists, non-alcoholic fatty liver disease, lipid profile, liver enzymes, alanine aminotransferase, gamma-glutamyl transferase, aspartate aminotransferase, alkaline phosphatase, triglycerides, total cholesterol, HDL cholesterol, LDL cholesterol, LDL particle number, dyslipidemia
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Humans, Lipids, Triglycerides, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.